CSL is consolidating its R&D team in an effort to better position the organization “for long-term success in a rapidly evolving global environment.” The Australia-based biopharma and manufacturer is ...

CSL to downsize one-third of R&D division, AFR reports Company has not confirmed the number of job reductions Shares up 3% at over 6-week high July 15 (Reuters) - Australian biotech giant CSL Ltd (CSL ...

CSL has gotten the Memo about the value of recombinant polyclonal immunoglobulin (IgG) antibodies. The company is signing on to a collaboration and option agreement with Memo Therapeutics that could ...

CSL Limited (OTCQX:CSLLY) (OTCQX:CMXHF), an Australian biotech focused on developing vaccines and blood-derived therapies, on Tuesday announced plans to invest approximately $1.5B in the U.S. over the ...

CSL announced the exit of Paul McKenzie as chief executive. Senior executive Gordon Naylor appointed interim CEO. Shares of Australian biotech firm CSL plunged to an 8-year low Wednesday after it ...

CSL Limited (OTC:CSLLY) and Arcturus Therapeutics (NASDAQ:ARCT) announced the results of a Phase 3 head-to-head study of ARCT-154, a self-amplifying (sa-mRNA) COVID-19 vaccine, compared to Pfizer ...

CSL recognized in Forbes and Statista's Best Large-sized Employer category for the fourth time since 2018. KING OF PRUSSIA, Pa., Feb. 21, 2023 /PRNewswire/ -- Global biotechnology leader CSL has again ...

Feb 14 (Reuters) - Australian biotech giant CSL Ltd said on Tuesday its first-half profit jumped 10%, beating analyst estimates, as a resurgence in blood plasma donations enabled it to boost sales and ...

Adds background and details on results in paragraphs 2-4 Aug 15 (Reuters) - Australia's CSL CSL.AX reported an annual profit on Tuesday that rose 8% as higher plasma collections helped the biotech ...